StreetInsider.com News Articles

Form 8-K Scienture Holdings, Inc. For: Sep 14

Tue, 22 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091848.html

Scienture signs deal to sell Rezenopy at 2,000 addiction clinics

Tue, 22 Sep 2026 08:16:51 -0400

Scienture Holdings (NASDAQ: SCNX) announced that its subsidiary, Scienture LLC, has entered into an exclusive sales, marketing, and distribution agreement with an unnamed distribution partner to supply Rezenopy (naloxone hydrochloride nasal spray 10 mg/0.11 mL) to opioid and substance-use disorder treatment centers across the United States.

Under the agreement, Rezenopy will be distributed through the partner's network of approximately 2,000 opioid treatment program (OTP) clinics and other addiction treatment centers nationwide. The distribution partner was not identified in the announcement.

Scienture said it will continue to commercialize Rezenopy outside the addiction treatment center market through wholesaler agreements, group purchasing organizations, and other

SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner

Tue, 22 Sep 2026 08:15:00 -0400

Agreement provides dedicated commercial channel for REZENOPY^™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States

According to IQVIA data (MAT July 2026), the U.S. naloxone market generated approximately $140 million in annual sales across 9.8 million units

COMMACK, NY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address

SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner

Tue, 22 Sep 2026 08:15:00 -0400

According to IQVIA data (MAT July 2026), the U.S. naloxone market generated approximately $140 million in annual sales across 9.8 million units

Form DEF 14A Scienture Holdings, Inc. For: Sep 18

Fri, 18 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260918/27080560.html

Form 8-K Scienture Holdings, Inc. For: Sep 14

Mon, 14 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260914/27058426.html

SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026

Wed, 09 Sep 2026 08:55:00 -0400

Management to Highlight Growing Commercial Momentum of Arbli^™ and the Commercial Launch of REZENOPY^™

COMMACK, NY, Sept. 09, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that management will participate in the H.C. Wainwright 28th Annual Global Investment Conference being held September 14 – 16, 2026 in New York City.

During the presentation, management

SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026

Wed, 09 Sep 2026 08:55:00 -0400

Management to Highlight Growing Commercial Momentum of Arbli^™ and the Commercial Launch of REZENOPY^™

During the presentation, management

Form 8-K Scienture Holdings, Inc. For: Aug 14

Thu, 20 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260820/26956178.html

Form 8-K Scienture Holdings, Inc. For: Aug 14

Thu, 20 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260820/26956178.html

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Fri, 14 Aug 2026 08:08:00 -0400

Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base

Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million

Q2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million

Commenced Commercial Launch of REZENOPY™, Establishing the Company’s Second Commercial Product and Expanding Its Revenue-Generating Portfolio

COMMACK, NY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Fri, 14 Aug 2026 08:08:00 -0400

Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base

Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million

Q2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million

Commenced Commercial Launch of REZENOPY™, Establishing the Company’s Second Commercial Product and Expanding Its Revenue-Generating Portfolio

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Fri, 14 Aug 2026 08:08:00 -0400

Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base

Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million

Q2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million

Commenced Commercial Launch of REZENOPY™, Establishing the Company’s Second Commercial Product and Expanding Its Revenue-Generating Portfolio

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Fri, 14 Aug 2026 08:08:00 -0400

Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base

Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million

Q2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million

Commenced Commercial Launch of REZENOPY™, Establishing the Company’s Second Commercial Product and Expanding Its Revenue-Generating Portfolio

Form 10-Q Scienture Holdings, Inc. For: Jun 30

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920921.html

Form 10-Q Scienture Holdings, Inc. For: Jun 30

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920921.html

Scienture launches 10mg naloxone nasal spray Rezenopy nationwide

Wed, 12 Aug 2026 08:05:15 -0400

Scienture Holdings (NASDAQ: SCNX) announced the commercial launch of Rezenopy (naloxone hydrochloride) Nasal Spray 10 mg, including fulfillment of initial purchase orders to U.S. pharmaceutical wholesalers, according to a company statement dated Aug. 12, 2026.

Rezenopy, which received FDA approval on April 19, 2024, is described by the company as the highest-dose FDA-approved naloxone hydrochloride nasal spray available in the United States. The product delivers 10 mg of naloxone hydrochloride in a single-use nasal spray device indicated for the emergency treatment of known or suspected opioid overdose in adult and pediatric patients.

Scienture acquired exclusive U.S. commercialization rights to Rezenopy through a

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray

Wed, 12 Aug 2026 08:05:00 -0400

Commercial launch supported by a dedicated national sales force, payer and institutional access, and multi-channel marketing campaign supporting adoption of REZENOPY^™

Targeting continued commercial execution through the end of 2026 by expanding payer coverage, broadening product access, and increasing institutional adoption within the approximately $143 million U.S. naloxone market based on annual sales, which represents annual demand of roughly 9.8 million units

COMMACK, NY, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients,

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray

Wed, 12 Aug 2026 08:05:00 -0400

Commercial launch supported by a dedicated national sales force, payer and institutional access, and multi-channel marketing campaign supporting adoption of REZENOPY^™

Scienture to ship naloxone nasal spray to wholesalers in July

Thu, 09 Jul 2026 08:06:02 -0400

Scienture Holdings (NASDAQ: SCNX) announced it has completed manufacturing of commercial launch inventory for REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg and plans to begin shipping the product to U.S. pharmaceutical wholesalers later in July, with commercial availability expected in August.

REZENOPY™ is a single-use nasal spray indicated for the emergency treatment of known or suspected opioid overdose. The company claims it is the highest-dose FDA-approved naloxone hydrochloride nasal spray available in the United States. The product received FDA approval on April 19, 2024.

According to IQVIA data for the 12 months ending April 2026, the U.S. naloxone market generated approximately $144

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

Thu, 09 Jul 2026 08:05:00 -0400